Ben Goldacre writes about Glaxo’s, as well as the pharmaceutical industry’s, history of broken promises regarding access to clinical trial data.
Support MIA
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.
